<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6275">
  <stage>Registered</stage>
  <submitdate>20/01/2017</submitdate>
  <approvaldate>20/01/2017</approvaldate>
  <nctid>NCT03029624</nctid>
  <trial_identification>
    <studytitle>eCoin Tibial Nerve Stimulation for OAB</studytitle>
    <scientifictitle>Subcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>111-3175</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Urgency Urinary Incontinence</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - eCoin

Experimental: Treatment Arm - Treatment Arm receives implanted eCoin device and therapy is turned ON.


Treatment: devices: eCoin
Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incontinent Episodes - The change in number of incontinence episodes from baseline to three months post-activation.</outcome>
      <timepoint>Baseline to three months post-activation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>System and Procedure Related AEs - Incidence of System and Procedure Related Adverse Events from implantation to one month post-implantation.</outcome>
      <timepoint>Implantation to one month post-implantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>MAEs - Incidence of all Major Adverse Events from baseline to 3 months post-activation.</outcome>
      <timepoint>Baseline to 3 months post-activation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Women and men 18 years and older.

          2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and
             stress incontinence with a predominant urgency component, for at least 6 months
             (self-reported).

          3. Individual has at least four urgency incontinence episodes on a three-day voiding
             diary with at least one episode per 24 hour time period

          4. Individual with urinary frequency, defined as an average of greater than or equal to 8
             times/24 hours (ie. a total of greater than or equal to 24 micturitions on a 3 day
             diary)

          5. Individual is unresponsive to, inadequately responsive to, or intolerant of
             behavioral, rehabilitation, and pharmacologic therapy.

          6. Individual is able to give his or her written, informed consent.

          7. Individual is mentally competent and able to understand all study requirements.

          8. Individual is willing and able to complete a 3-day voiding diary and quality of life
             questionnaire.

          9. Individual is without pharmacological treatment of overactive bladder (antimuscarinics
             and beta-3 agonists) for 2 weeks prior to screening.

         10. The individual demonstrates a positive nerve integrity test.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Individual has predominantly stress urinary incontinence

          2. Individual has clinically significant bladder outlet obstruction.

          3. Individual has clinically significant pelvic organ prolapse.

          4. Individual has abnormal post void residual (i.e., greater than 150 cc).

          5. Individual has clinically significant urethral stricture disease or bladder neck
             contracture

          6. Individual has an active urinary tract infection at time of enrollment.

          7. Individual has recurrent urinary tract infections defined as 4 or more UTI's per year.

          8. Individual has morbid obesity.

          9. Individual has had positive urine cytology or diagnosis of bladder or prostate cancer.

         10. Individual has neurogenic bladder dysfunction.

         11. Individual is taking an alpha-blocker for benign prostatic hyperplasia.

         12. Individual is pregnant or intends to become pregnant during the study.

         13. Patient is breast feeding or is less than 9-month post-partum.

         14. Individual has the presence of urinary fistula, bladder stone, or interstitial
             cystitis.

         15. Individual has uncontrolled diabetes mellitus.

         16. Individual has a cardiac pacemaker or implanted defibrillator.

         17. Individual has been previously treated with sacral nerve stimulation.

         18. Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to
             enrollment.

         19. Individual has been treated with percutaneous tibial nerve stimulation within the
             previous 12 weeks prior to enrollment.

         20. Individual requires regular Magnetic Resonance Imaging for other health care
             conditions. (ASK)

         21. Individual has a clotting or bleeding disorder; antiplatelet and anticoagulant therapy
             may be continued or held at the discretion of the investigator

         22. Individual has a clinically significant peripheral neuropathy.

         23. Individual is neutropenic or immunocompromised.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>3/04/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Valencia Technologies Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is a single arm, prospective study of the safety and effectiveness of the Valencia
      Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with
      refractory urgency urinary incontinence.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03029624</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sharon English, MD</name>
      <address>Urology Associates</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>